{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:43:45Z","timestamp":1793515425131,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Comprehensive Cancer Centre the Netherlands, Eindhoven, The Netherlands"},{"name":"Netherlands Organization for Scientific Research","award":["NWO #480-08-009"],"award-info":[{"award-number":["NWO #480-08-009"]}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"crossref","award":["#UVT-2009-4349"],"award-info":[{"award-number":["#UVT-2009-4349"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Netherlands Organization for Scientific Research","award":["#451-10-041"],"award-info":[{"award-number":["#451-10-041"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ygyno.2014.09.016","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T21:23:42Z","timestamp":1412112222000},"page":"510-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"title":["Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry"],"prefix":"10.1016","volume":"135","author":[{"given":"Nicole P.M.","family":"Ezendam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Pijlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Bhugwandass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.M.","family":"Pruijt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floortje","family":"Mols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Caroline","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.A.","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke V.","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.09.016_bb0005","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ejca.2008.06.001","article-title":"Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990\u20132006 in the southeastern Netherlands","volume":"44","author":"Sukel","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0010","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.ejca.2010.02.013","article-title":"Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands","volume":"46","author":"Dassen","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0015","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejca.2010.01.025","article-title":"Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989\u20132006","volume":"46","author":"Elferink","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.maturitas.2012.10.007","article-title":"Effect of diabetes on endometrial cancer recurrence and survival","volume":"74","author":"Zanders","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0025","first-page":"18","article-title":"Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies","volume":"70","author":"Beijers","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.2011.115","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment","volume":"90","author":"Pachman","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0035","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies","volume":"12","author":"Gutierrez-Gutierrez","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0045","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","article-title":"Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane)","volume":"98","author":"Cella","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0050","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00520-011-1336-0","article-title":"Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure","volume":"20","author":"Driessen","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0055","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s11136-010-9670-0","article-title":"Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma","volume":"19","author":"Kim","year":"2010","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0060","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0065","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jjco\/hyg083","article-title":"Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model","volume":"33","author":"Morita","year":"2003","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1529-8027.2009.00230.x","article-title":"Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia","volume":"14","author":"Ramchandren","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0075","first-page":"773","article-title":"A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB\u2013IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation","volume":"40","author":"Sorbe","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1525-1438.2003.13603.x","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0085","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejca.2011.04.034","article-title":"The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts","volume":"47","author":"van de Poll-Franse","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0090","series-title":"Maandstatistiek van de bevolking","first-page":"32","article-title":"Sociaal-economische status indicator op postcodeniveau [in Dutch]","volume":"50","author":"Van Duijn","year":"2002"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/art.10993","article-title":"The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research","volume":"49","author":"Sangha","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00449426","article-title":"A validation study of the domains of the core EORTC quality of life questionnaire","volume":"2","author":"Niezgoda","year":"1993","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0105","series-title":"The EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0110","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.12.421","article-title":"A study of symptoms described by ovarian cancer survivors","volume":"125","author":"Stavraka","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0130","first-page":"3969","article-title":"Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology","volume":"32","author":"Richter","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0135","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/WCO.0b013e32834a87b7","article-title":"Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations","volume":"24","author":"Koike","year":"2011","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0140","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/diacare.27.7.1591","article-title":"Prevalence of lower-extremity disease in the US adult population >=40years of age with and without diabetes: 1999\u20132000 national health and nutrition examination survey","volume":"27","author":"Gregg","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","article-title":"Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report","volume":"37","author":"Cull","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14740338.2011.543417","article-title":"Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence","volume":"10","author":"Balayssac","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0155","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0160","first-page":"73","article-title":"Docetaxel in the treatment of ovarian cancer","volume":"16","author":"Kavanagh","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0165","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel\u2013carboplatin versus paclitaxel\u2013carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0170","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S1470-2045(14)70219-0","article-title":"Carboplatin plus paclitaxel once a week versus every 3weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0175","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdt527","volume":"25","author":"Harano","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.09.016_bb0185","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2009.10.073","article-title":"The potential benefit of 6 vs. 3cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study","volume":"116","author":"Chan","year":"2010","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814013432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814013432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T18:29:34Z","timestamp":1538159374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814013432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0090825814013432"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}